<DOC>
	<DOC>NCT01142193</DOC>
	<brief_summary>The purpose of this study is to examine the safety and effectiveness of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Subject has a confirmed diagnosis of partialonset seizures with or without secondary generalization for at least 12 months prior to Visit 1. Currently on a stable dosing regimen of 1 to 3 AEDs for at least 4weeks prior to Visit 1 (12 weeks for phenobarbital and primidone). Have a minimum of 8 partialonset seizures and no more than 21 consecutive seizure free days, during the 8week baseline. Have a history of seizure episodes lasting less than 30 minutes in which several seizures occur with such frequency that the initiation and completion of each individual seizure cannot be distinguished, within 3 months prior to Visit 1. Have a history of pseudoseizures, or status epilepticus, within 3 months prior to Visit 1. Have a history of metabolic acidosis, nephrolithiasis, ureterolithiasis, or narrow angle glaucoma. Have a history of suicidal attempts, suicidal ideation, or uncontrolled psychiatric illness within 2 years of Visit 1. Currently taking, or have taken felbamate within the past 18 months, or have taken vigabatrin in the past. Have taken topiramate within the past 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>partial onset seizure</keyword>
	<keyword>adjunctive therapy</keyword>
</DOC>